CU22732A1 - Mutantes de estreptoquinasa - Google Patents

Mutantes de estreptoquinasa

Info

Publication number
CU22732A1
CU22732A1 CU1998119A CU1998119A CU22732A1 CU 22732 A1 CU22732 A1 CU 22732A1 CU 1998119 A CU1998119 A CU 1998119A CU 1998119 A CU1998119 A CU 1998119A CU 22732 A1 CU22732 A1 CU 22732A1
Authority
CU
Cuba
Prior art keywords
streptokinase
mutants
present
skc
obtaining
Prior art date
Application number
CU1998119A
Other languages
English (en)
Inventor
Griego Martha De Jesus Gonzalez
Escalona Elder Pupo
Ojalvo Ariana Garcia
Menendez Alina Seralena
Madrazo Isis Del Carmen Torrens
Garcia Jose De Jesus De La Fuente
Masso Julio Raul Fernandez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1998119A priority Critical patent/CU22732A1/es
Priority to AU43424/99A priority patent/AU769916B2/en
Priority to CA002277554A priority patent/CA2277554C/en
Priority to US09/374,038 priority patent/US6309873B1/en
Priority to EP99202639A priority patent/EP0985729B1/en
Priority to AT99202639T priority patent/ATE294239T1/de
Priority to DE69924932T priority patent/DE69924932D1/de
Priority to US09/658,179 priority patent/US6413759B1/en
Publication of CU22732A1 publication Critical patent/CU22732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

La presente invención está relacionada con el campo de la biotecnología y en particular con un método de obtención de mutantes a partir de la estreptoquinasa, con las moléculas obtenidas a partir de dicho método, así como con los vectores de expresión y los microorganismos para su obtención por vía recombinante. El objetivo de la presente invención es lograr mutantes de estreptoquinasa a partir de modificaciones del gen skc-2 codificante para la estreptoquinasa SKC-2 (Heberkinasa®), de manera que los mutantes obtenidos mantengan su capacidad de formación del complejo activador y que tengan reducida antigenicidad, que puedan constituir una alternativa preferente a la estreptoquinasa nativa para la terapia trombolítica. Las moléculas obtenidas a partir de la presente invención pueden ser empledas en el tratamiento de enfermedades como el infarto del miocardio, el tromboembolismo pulmonar, así como en complicaciones quirúrgicas y otros casos de trombosis.
CU1998119A 1998-08-14 1998-08-14 Mutantes de estreptoquinasa CU22732A1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CU1998119A CU22732A1 (es) 1998-08-14 1998-08-14 Mutantes de estreptoquinasa
AU43424/99A AU769916B2 (en) 1998-08-14 1999-08-05 Streptokinase mutants
CA002277554A CA2277554C (en) 1998-08-14 1999-08-06 Streptokinase mutants
US09/374,038 US6309873B1 (en) 1998-08-14 1999-08-13 Streptokinase mutants
EP99202639A EP0985729B1 (en) 1998-08-14 1999-08-13 Streptokinase mutants
AT99202639T ATE294239T1 (de) 1998-08-14 1999-08-13 Streptokinasemutanten
DE69924932T DE69924932D1 (de) 1998-08-14 1999-08-13 Streptokinasemutanten
US09/658,179 US6413759B1 (en) 1998-08-14 2000-09-08 Streptokinase mutants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998119A CU22732A1 (es) 1998-08-14 1998-08-14 Mutantes de estreptoquinasa

Publications (1)

Publication Number Publication Date
CU22732A1 true CU22732A1 (es) 2002-02-28

Family

ID=5459400

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1998119A CU22732A1 (es) 1998-08-14 1998-08-14 Mutantes de estreptoquinasa

Country Status (7)

Country Link
US (2) US6309873B1 (es)
EP (1) EP0985729B1 (es)
AT (1) ATE294239T1 (es)
AU (1) AU769916B2 (es)
CA (1) CA2277554C (es)
CU (1) CU22732A1 (es)
DE (1) DE69924932D1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6348567B1 (en) * 1995-12-06 2002-02-19 Cv Molecular Therapeutics Inc. Peptides and their use to ameliorate cell death
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
NZ589557A (en) * 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
ES2552337T3 (es) 2009-03-03 2015-11-27 Grifols Therapeutics Inc. Procedimientos para la preparación de plasminógeno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2238180A (en) * 1989-11-14 1991-05-22 Stc Plc Cable laying equipment
CU22277A1 (es) * 1990-05-23 1995-01-31 Cigb Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase

Also Published As

Publication number Publication date
US6413759B1 (en) 2002-07-02
CA2277554C (en) 2004-11-02
ATE294239T1 (de) 2005-05-15
EP0985729B1 (en) 2005-04-27
EP0985729A3 (en) 2000-05-31
EP0985729A2 (en) 2000-03-15
AU4342499A (en) 2000-03-09
CA2277554A1 (en) 2000-02-14
AU769916B2 (en) 2004-02-12
DE69924932D1 (de) 2005-06-02
US6309873B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
PT1077072E (pt) Processo in vitro para produzir uma protese homologa de valvula cardiaca ou uma protese homologa de vaso sanguineo
ATE89006T1 (de) Expression von menschlichem proapolipoprotein a- 1.
DE60238416D1 (de) Plasmaprotein-matritzes und verfahren zu ihrer herstellung
AR002832A1 (es) Haloperoxidasas obtenidas de curvularia verruculosa, acidos nucleicos que las codifican, vector recombinante, celula huesped recombinante, metodos paraproducir dichas haloperoxidasas, metodo para oxidar un ion haluro, metodo para halogenar un compuesto y metodo para matar celulas microbianas o inhibir su
DE602005011486D1 (de) Säure-pilzprotease bei der fermentation von nichtlöslichen stärkesubstraten
ATE370161T1 (de) Herstellung von polyketiden und anderen natürlichen produkten
ATE458817T1 (de) Klonierung und rekombinante herstellung von phospholipase aus vespidae und immunologische therapien darauf basierend
CU22732A1 (es) Mutantes de estreptoquinasa
Zhong et al. Purification and characterization of a new L-amino acid oxidase from Daboia russellii siamensis venom
Girón et al. Functional characterization of fibrinolytic metalloproteinases (colombienases) isolated from Bothrops colombiensis venom
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
ZA202110356B (en) Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
MX9600380A (es) Proceso de extraccion de proteinas periplasmicas de microorganismos procarioticos en presencia de arginina.
BR112021022916A2 (pt) Bactérias produtoras de ácido lático frutofílico
CO5060478A1 (es) Secuencia del gen relacionado con agiopoyetina scarface 3
BR0107655A (pt) Polinucleotìdeo isolado, vetor de expressão recombinante, polipeptìdeo, célula, método para produzir o polipeptìdeo, e, composição farmacêutica
Kunhiraman et al. Least hemolytic, 12.6 kDa, plasmin-like fibrinolytic protease from marine Penicillium steckii KU1
Kahn et al. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector‐based COVID‐19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al.
Kawakatsu et al. Interaction of actin filaments with the plasma membrane in Amoeba proteus: studies using a cell model and isolated plasma membrane
Brewin et al. Structure and development of infection threads
AR007624A1 (es) Procedimiento para la fabricacion de un producto biologico, estabilizante de las precipitaciones proteicas de los vinos blancos, el producto asiobtenido, el procedimiento de seleccion de levaduras para su aplicacion en dicho procedimiento y el procedimiento de tratamiento de los vinos blancos con
DK1472347T3 (da) Forbedret proteinekspression i Bacillus Subtilis
MX168450B (es) Metodo para regular la expresion de un gen exterior controlando la concentracion de azucar en un medio y el procedimiento para producir un producto de gen exterior